Diarrhea, Dysentery, Shigella, Shigellosis
Conditions
Keywords
Azithromycin, Ciprofloxacin, Children, Dysentery, Vietnam
Brief summary
The purpose of this study is to assess the efficacy of 3 days of azithromycin (AZI) compared to 3 days of ciprofloxacin (CIP) (standard-of-care) for the treatment of children hospitalised with dysentery in Ho Chi Minh City.
Detailed description
Antimicrobial resistance is a well-established international healthcare crisis and children with diarrhoeal infections represent a significant proportion of the global infectious disease burden. With the increasing rates of antimicrobial resistance observed in the organisms associated with children presenting with dysentery in Vietnam and the investigator's capacity to demonstrate international transmission events, new data regarding alternative treatment options such as azithromycin, in particular for the new highly-antimicrobial resistant S. sonnei, are urgently needed. The study team will perform a phase IV open label randomised controlled trial to compare the efficacy of AZI to CIP (standard-of-care) for the treatment of children hospitalised with dysentery in Ho Chi Minh City, Vietnam. Children aged 6 to 60 months presenting to the participating hospital with symptoms/signs of dysentery (diarrhoea with blood and/or mucus accompanied by 1 or more of: fever ≥37.8°C, abdominal pain and /or tenesmus) within the previous 72 hours will be enrolled to the study. After enrolment, participants will be managed according to WHO and local algorithms for children with bloody diarrhoea. In addition, after providing a stool sample, children will be randomly allocated to receive CIP 15mg/kg body weight/ twice daily or AZI 10mg/kg body weight/ daily for 3 days. After enrolment, children will be reviewed for clinical and microbiological response to treatment.
Interventions
DRUGCiprofloxacin
Fluoroquinolone, ATC code: J01MA02 DNA-gyrase and topoisomerase IV inhibitor
DRUGAzithromycin
Macrolide, ATC code: J01FA10 Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis.
Sponsors
Number 2 Children's Hospital, Ho Chi Minh City
University of Liverpool
Oxford University Clinical Research Unit, Vietnam
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Randomization will be 1:1 to either AZI or CIP. Block randomization with stratification by hospital of enrolment, and variable block sizes of 4 and 6, respectively, will be used to assign subjects to treatment. The randomization list will be generated according to standard operating procedures without our organization. In brief, the Research Biostatistician (RB) will generate a randomization list using an in-house statistical code and transfer it to the central Study Pharmacist (SP). The SP will change the random seed to blind the RB and then run the code to prepare the final randomization list for treatment preparation. The randomization list will be saved and stored on a secure server. After enrolment, children will be randomly allocated to one of two treatment arms: in one arm, children will be treated with the current standard of care, oral CIP 15mg/kg BW /twice daily for 3 days, while those in the other arm will receive oral AZI 10mg/kg BW/daily for 3 days.
Eligibility
Sex/Gender
ALL
Age
6 Months to 60 Months
Healthy volunteers
No
Inclusion criteria
1. Male or female aged 6 months to 60 months at time of hospital presentation. 2. Have symptoms and/or signs of dysentery, specifically passing stools containing mucus and/or blood with/without abdominal pain, tenesmus or fever (≥37.8˚C). 3. Be eligible for treatment with oral medication in the opinion of the admitting physician (i.e. no clinical requirement for parenteral treatment on admission). 4. Be within 72 hours of the onset of signs/symptoms. 5. Have a parent/guardian present at admission who can provide written informed consent.
Exclusion criteria
1. Those known to have specific medical (patients with known prolongation of the QT interval, congenital long QT syndrome)/surgical conditions which may affect disease severity/presentation or response to treatment (e.g. affecting antimicrobial absorption), including: 1. gastrointestinal abnormalities, including short bowel syndrome, chronic (inflammatory or irritable) bowel disease. 2. inherited or acquired immune system deficiency rendering the patient immunocompromised, including chronic/long-term steroid treatment or other immunosuppressive treatment 2. Presentation with severe infection requiring parenteral antimicrobial treatment, including shock jaundice, extensive gastrointestinal bleeding, convulsion , drowsiness or coma, reduced or less movement when stimulated, tachypnea \> 60 times per minute, grunting, chest retraction, refuse to suck. 3. Known hypersensitivity to any of the trial drugs (CIP or AZI). 4. Coexisting infection requiring other or additional antimicrobials to be prescribed/ administered.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess the Clinical treatment failure between treatment groups. | after 120 hours of start of either treatment. | Clinical treatment failure including: fever ≥38.0°C or the persistence of signs or symptoms of the infection (vomiting, abdominal pain, passing loose stools more than 3 times per 24 hours ( with blood and mucus, blood or mucus, without both)) |
| Assess the microbiological treatment failure between treatment groups. | after 72 hours of start of either treatment. | The microbiological treatment failure is assessed by positive PCR stool with original pathogen after day 3 of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess the time to resolution of objective markers of infection and inflammation, including cessation of culture- and PCR-confirmed Shigella shedding, normalization of blood total white cell count, C-reactive protein and stool lipocalin | at enrolment, day 7th (+3 days) and day 28th (+3 days) | Time to cessation of Shigella shedding in stool (PCR). |
| Measure differences in symptom duration between treatment groups by stratifying stool PCR. | 120 hours of start of either treatment. | Compare the duration of symptom ( from the onset to disappear) between the two groups. The duration of symptom will be stratified by stool PCR. |
| Assess the effects of antimicrobial exposure on the host microbiome, including diversity and abundance of specific bacterial species in stool. | at enrolment, day 7th (+3 days) and day 28th (+3 days). | The extend of intestinal microbial colonisation will be assessed by analyses of stool sample collected at enrolment, day 7th (+3 days) and day 28th (+3 days) |
| Assess the rates of adverse events associated with exposure to the antimicrobial agents used. | at enrolment, during 31 days after enrolment | Adverse effects of antimicrobial treatment, including (i) life-threatening events, (ii) events requiring drug discontinuation, (iii) mild adverse events that require additional medication to be used but not resulting in drug discontinuation. |
| Measure differences in symptom duration between treatment groups by stratifying stool culture. | 120 hours of start of either treatment. | Compare the duration of symptom ( from the onset to disappear) between the two groups. The duration of symptom will be stratified by stool culture. |
Countries
Vietnam
Outcome results
None listed